当前位置：药药网 / 数据中心 / 儿科标签更改电子表格2021
Harvoni
通用名称
ledipasvir/sofosbuvir
儿科标签批准日期
2019/11/15 0:00:00
特定指示/秒
Treatment of chronic hepatitis C virus infection in patients with severe renal impairment including patients with end stage renal disease on dialysis
标签更改摘要
- In patients with severe renal impairment, including those requiring dialysis, exposures of the inactive metabolite of sofosbuvir are increased.
- No data are available regarding the safety of Harvoni in pediatric patients with renal impairment.
- Postmarketing study.